ACG Wealth bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 968 shares of the medical equipment provider’s stock, valued at approximately $102,000.
Several other institutional investors and hedge funds have also bought and sold shares of ZBH. Gilman Hill Asset Management LLC increased its stake in Zimmer Biomet by 0.9% during the first quarter. Gilman Hill Asset Management LLC now owns 8,996 shares of the medical equipment provider’s stock worth $1,151,000 after purchasing an additional 81 shares during the period. SYM FINANCIAL Corp raised its stake in shares of Zimmer Biomet by 4.9% during the first quarter. SYM FINANCIAL Corp now owns 1,769 shares of the medical equipment provider’s stock worth $226,000 after purchasing an additional 82 shares during the last quarter. Roberts Glore & Co. Inc. IL raised its position in Zimmer Biomet by 1.0% in the first quarter. Roberts Glore & Co. Inc. IL now owns 8,323 shares of the medical equipment provider’s stock worth $1,065,000 after acquiring an additional 85 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in Zimmer Biomet by 5.7% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,837 shares of the medical equipment provider’s stock worth $235,000 after acquiring an additional 99 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its position in shares of Zimmer Biomet by 0.8% in the first quarter. Louisiana State Employees Retirement System now owns 13,200 shares of the medical equipment provider’s stock valued at $1,767,000 after buying an additional 100 shares in the last quarter. 89.39% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Zimmer Biomet
In other news, insider Zuilen Wilfred Van sold 531 shares of the business’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $105.22, for a total value of $55,871.82. Following the sale, the insider now owns 2,240 shares of the company’s stock, valued at approximately $235,692.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.73% of the company’s stock.
Zimmer Biomet Trading Down 2.0 %
NYSE:ZBH opened at $108.01 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.81 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.39 and a 12-month high of $153.76. The business has a 50 day simple moving average of $111.04 and a 200 day simple moving average of $115.44. The firm has a market capitalization of $22.66 billion, a P/E ratio of 99.09, a P/E/G ratio of 3.27 and a beta of 1.14.
Zimmer Biomet (NYSE:ZBH – Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The medical equipment provider reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.19. Zimmer Biomet had a return on equity of 12.20% and a net margin of 3.10%. The company had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.72 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 6.8 EPS for the current year.
Zimmer Biomet Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Thursday, September 29th. Zimmer Biomet’s dividend payout ratio is presently 88.07%.
Analyst Upgrades and Downgrades
ZBH has been the topic of a number of analyst reports. Piper Sandler decreased their price objective on Zimmer Biomet from $130.00 to $120.00 in a research note on Tuesday, August 2nd. Needham & Company LLC downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, May 27th. Citigroup raised their target price on Zimmer Biomet from $114.00 to $119.00 in a report on Wednesday, August 3rd. Stifel Nicolaus dropped their price objective on Zimmer Biomet from $140.00 to $120.00 in a report on Monday, July 18th. Finally, Morgan Stanley lifted their price objective on Zimmer Biomet from $115.00 to $120.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 3rd. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $133.50.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.
Receive News & Ratings for Zimmer Biomet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet and related companies with MarketBeat.com’s FREE daily email newsletter.